Lipid profiles and oxidative stress parameters in male and female hemodialysis patients

Molecular and Cellular Biochemistry

Volumn 353, Issue 1-2, 2011, Pages 59-63

  Osorio, A ^a   Ortega, E ^b,c   De Haro, T ^d   Torres, J M ^b,c   Sanchez P ^b   Ruiz Requena, E ^b  

^a HOSPITAL VIRGEN DE LA LUZ   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Atherosclerosis; CKD; Homocysteine; LDL; Ox LDL; Ox LDL AB

Indexed keywords

AUTOANTIBODY; CYANOCOBALAMIN; FOLIC ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDATIVE MODIFICATION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; OXIDATIVE STRESS;

AGED; ATHEROSCLEROSIS; BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES; VITAMIN B 12;

EID: 79959201526     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-011-0774-9     Document Type: Article

References (37)

1. Roob JM, Rabold T, Hayn T, Khoschsorur G, Resch U, Holzer H, Winklhofer-Roob BM (2001) Ex vivo low-density lipoprotein oxidizability and in vivo lipid peroxidation in patients on CAPD. Kidney Int 78S:128-136 Suppl
2. Van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, Van Leusen R (2003) Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C reactive protein and in vivo oxidized LDL. J Nephrol 16:238-244 (Pubitemid 37304080)
3. Locatelli F, Del Vecchio L, Manzoni C (1998) Morbidity and mortality on maintenance haemodialysis. Nephron 80:380-400 (Pubitemid 28554685)
4. Van Kuijk JP, Flu WJ, Chonchol M, Welten GMJM, Verhagen HJM, Bax JJ, Poldermans D (2010) The prevalence and prognostic implications of polyvascular atherosclerotic disease in patients with chronic kidney disease. Nephrol Dial Transplant 25:1882-1888
5. Junyent M, Martinez M, Borras M, Bertriu A, Coll B, Craver L, Marco MP, Sarró F, Valdivieso JM, Fernanadez E (2010) Usefulness of imaging techniques and novel biomarkers in the prediction of cardiovascular risk in patients with chronic kidney disease in Spain: the NEFRONA project. Nefrologia 30:119-126
6. Foley RN, Parfrey PS, Sarnak MJ (1998) CAD in chronic renal disease: clinical epidemiology of CAD in chronic renal disease. Am J Kidney Dis 32:112-119
7. Wanner C, Zimmerman J, Quaschning T, Galle J (1997) Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int 62:53-55 Suppl
8. Nestel PJ, Fidge NH, Tan MH (1982) Increased lipoproteinremnant formation in chronic renal failure. New Eng J Med 307:329-333 (Pubitemid 12082192)
9. Kasiske BL (1998) Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32:142-156
10. Brunzell JD, Albers JJ, Haas LB, Goldberg AP, Agadaa L, Sherrard DJ (1997) Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 26:903-907
11. Senti M, Romero R, Pedro-Botert J, Pelegri A, Nogues X, Rubies-Part J (1992) Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 41:1394-1399
12. Pawlak K, Pawlak D, Mysliwiec M (2004) Oxidative stress influences CC-Chemokine levels in hemodialyzed patients. Nephron Physiol 96:105-112
13. Massy ZA, Nguyen-Khoa T (2002) Oxidative stress and chronic renal failure: Markers and management. J Nephrol 15:336-341
14. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B (2001) Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 12:2747-2752 (Pubitemid 33115422)
15. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T (1999) Strong association between malnutrition, inflammation, and atherosclerosis in renal failure. Kidney Int 55:1899-1911 (Pubitemid 29197978)
16. Schlondorff D (1993) Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis 22:72-82
17. Lyons TJ, Jenkins AJ (1997) Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol 8:174-180 (Pubitemid 27290464)
18. Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S (1999) Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 142:67-77 (Pubitemid 28551811)
19. O'Byrne D, Devaraj S, Islam KN, Collazo R, McDonald L, Grundy S (2001) Low-density (LDL)-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized-LDL in chronic renal failure patients on dialysis therapy. Metabolism 50:207-215 (Pubitemid 32170835)
20. Bergesio F, Monzani G, Cinti R, Cirami C, Martinelli F, Salvadori M, Tosi PL (2001) Autoantibodies against oxidized LDL in chronic renal failure: role of renal function, diet, and lipids. Nephron 87:127-133 (Pubitemid 32215823)
21. Osorio A, Ortega E, Ruiz-Requena E (2008) Two models of homocysteine behaviour in acute myocardial infarction. Clin Biochem 41:277-281
22. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH (2001) The kidney and homocysteine metabolism. J Am Soc Nephrol 12:2181-2189 (Pubitemid 32880357)
23. Mayer EL, Jacobsen DW, Robinson K (1996) Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 27:517-527 (Pubitemid 26081913)
24. Tinahones FJ, Gómez-Zumaquero FM, Garrido-Sanchez L, Garcia-Fuentes E, Rojo-Martinez G, Esteva I, Ruiz de Adana MS, Cardona F, Soriguer F (2005) Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population. J Lipid Res 46:452-457 (Pubitemid 43109781)
25. Karvonen J, Paivansalo M, Kesaniemi YA, Horkko S (2003) Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108:2107-2112 (Pubitemid 37337587)
26. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Omata M, Kimura K (2006) Urinary livertype fatty acid binding protein as a useful biomarker in chronic kidney disease. Moll Cell Biochem 284:175-182 (Pubitemid 44404425)
27. Tokuyama H, Kelly DJ, Zhang Y, Gow RM, Gilbert RE (2007) Macrophage infiltration and cellular proliferation in the nonischemic kidney and heart following prolonged unilateral renal ischemia. Nephron Physiol 106:54-62 (Pubitemid 47026181)
28. Kushiya F, Wada H, Sakakura M, Mori Y, Gabazza EC, Nishikawa M, Nobori T, Noguchi M, Izumi K, Nakasaki T, Takagi M, Shiku H (2003) Effects of lipid abnormalities on arteriosclerosis and hemostatic markers in patients under hemodialysis. Clin Appl Thromb Hemost 9:203-210 (Pubitemid 37070128)
29. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I (2000) α-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 150:217-224
30. Valli A, Carrero JJ, Qureshi AR, Gariboto G, Barány P, Axelsson J, Lindholm B, Stenvinkel P, Anderstam B, Suliman ME (2008) Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients. Clin Chim Acta 395:106-110
31. Westphal S, Dierkes J, Luley C (2001) Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 358:39-40 (Pubitemid 32709742)
32. Zinellu A, Sotgia S, Deiana L, Carru C (2005) Quantification of thiol-containing amino acids linked by disulfides to LDL. Clin Chem 51:658-660 (Pubitemid 40300250)
33. Stehouwer C, Jacobs C (1998) Abnormalities of vascular function in hyperhomocysteinemia: Relationship to atherothrombotic disease. Eur J Pediatr 157:107-111
34. Abdulle AM, Gillett MP, Abouchacra S, Sabri SM, Rukhaimi MA, Obineche EN, Singh J (2007) Low IGF-1 levels are associated with cardiovascular risk factors in haemodialysis patients. Mol Cell Biochem 302:195-201 (Pubitemid 47202335)
35. Higashi Y, Sukhanov S, Anwar A, Shai SY, Delafontaine P (2010) IGF-1, oxidative stress and atheroprotection. Trends Endocrinol Metab 21:245-254
36. Fallest-Strobl PC, Koch DD, Stein JH, McBride PE (1997) Homocysteine: a new risk factor for atherosclerosis. Am Fam Physician 56:1607-1612
37. Dierkes J, Westphal S, Luley C (1999) Serum homocysteine increase after therapy with fenofibrate or bezafibrate. Lancet 354:219-220 (Pubitemid 29329164)